George Abercrombie - Theravance Insider

THRX -- USA Stock  

null 9.81  9.81  9,223,372,036,855%

Senior Vice President - Corporate Partnerships, Commercial
Mr. George B. Abercrombie is Senior Vice President Corporationrationrate Partnerships Commercial of the Company. Mr. George B. Abercrombie RPh MBA joined Innoviva Inc. in June 2014. Prior to joining Innoviva Mr. Abercrombie served as the President and Chief Executive Officer of HoffmannLa Roche Inc. from 2001 to 2009 where he was responsible for the US and Canadian business divisions. From 1993 to 2001 Mr. Abercrombie worked at Glaxo and its successor companies including as Senior Vice President of Commercial Operations for Glaxo Wellcome Inc. He is the Chairman of the Board of BioCryst Pharmaceuticals Inc. and also serves as a board member of numerous other healthcarerelated organizations including Project Hope and the North Carolina GlaxoSmithKline Foundation
Age: 60  President Since 2014  MBA    
Abercrombie holds an MBA from Harvard Business School and a BS from the University of North Carolina at Chapel Hill, School of Pharmacy.

George Abercrombie Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 1.82 % which means that it generated profit of $1.82 on every $100 spent on asset. This is way below average.
The company currently holds 744.09 M in liabilities with Debt to Equity (D/E) ratio of 1.09 which is about average as compared to similar companies. Theravance has Current Ratio of 19.44 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Entity Summary

Theravance, Inc., a royalty management company, is focused on developing respiratory products. Theravance (THRX) is traded on NASDAQ in USA. It is located in South San Francisco, CA and employs 13 people.

Theravance Leadership Team

Catherine Friedman, Director
Michael Aguiar, CEO, MBA
Barbara Duncan, Director
Paul Pepe, Director
George Abercrombie, President, MBA
Patrick LePore, Director
James Tyree, Director
Eric dEsparbes, CFO
Terrence Kearney, Director
Michael Faerm, SVP, MBA
Theodore Witek, SVP, MBA
William Waltrip, Director

Stock Performance Indicators

Current Sentiment - THRX

Theravance Investor Sentiment
Most of Macroaxis users are at this time bullish on Theravance. What is your outlook on investing in Theravance? Are you bullish or bearish?
98% Bullish
2% Bearish
Currently Active Assets on Macroaxis
Purchased few shares of
few hours ago
Traded for 79.19
Purchased few shares of
few hours ago
Traded for 179.93
Purchased few shares of
few hours ago
Traded for 281.04
Sold one share of
few hours ago
Traded for 42.84
Purchased over 90 shares of
few hours ago
Traded for 45.12
Also please take a look at World Market Map. Please also try Volatility Analysis module to get historical volatility and risk analysis based on latest market data.